Clinical trial
Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal…
NCT00380887 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00380887 |
|---|---|
| Title | Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women |
| Official title | An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal… |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Postmenopause |
| Intervention type | Drug |
| Interventions | Premarin |
| Enrollment | 54 |
| Start date | Jun 1, 2005 |
| First posted | Sep 27, 2006 |
| Last update posted | Sep 27, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: